Centessa Pharmaceuticals PLC Form 4 insider transactions

Centessa Pharmaceuticals CEO Saurabh Saha sold 55,000 ordinary shares at an average price of $17.4374, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Centessa Pharmaceuticals' Chief Technology & Quality Officer, Tia L. Bush, engaged in multiple stock transactions, including sales and option exercises, according to a recent SEC filing.

Centessa Pharmaceuticals' General Counsel, Iqbal J. Hussain, acquired and disposed of company stock and options, according to a recent SEC filing.

Centessa Pharmaceuticals' Chief People Officer, Karen M. Anderson, executed stock sales and option exercises under a pre-arranged 10b5-1 trading plan.

Centessa Pharmaceuticals CEO, Saurabh Saha, executed a sale of 87,496 ordinary shares at an average price of $18.4609, while also acquiring the same number of shares through option exercise at $5.84.

Centessa Pharmaceuticals CEO, Saurabh Saha, engaged in stock transactions, including both acquisition and disposal of shares, under a pre-arranged 10b5-1 trading plan.

Centessa Pharmaceuticals' Chief Business Officer, Gregory M. Weinhoff, exercised options and sold 10,000 shares of company stock on November 25, 2024.

Centessa Pharmaceuticals CEO, Saurabh Saha, executed multiple sales of ordinary shares and exercised stock options over several days, according to a recent SEC Form 4 filing.

Centessa Pharmaceuticals CEO, Saurabh Saha, exercised stock options and sold shares on November 13, 2024, according to a recent SEC filing.

Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals plc, sold 11,742 ordinary shares at an average price of $15.3831.

Centessa Pharmaceuticals CEO Saurabh Saha sold a portion of his ordinary shares between October 21 and October 23, 2024, under a pre-arranged Rule 10b5-1 trading plan.

David M. Chao, Chief Administrative Officer of Centessa Pharmaceuticals plc, disposed of shares to cover tax withholding obligations related to vesting restricted share units.

Iqbal Hussain, General Counsel of Centessa Pharmaceuticals, reports the disposal of 7,520 ordinary shares to cover tax obligations and discloses beneficial ownership of 197,490 ordinary shares directly and 5,500 indirectly through a spouse.

Gregory Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, disposed of shares to cover tax withholding obligations related to vesting restricted share units.

CEO Saurabh Saha reports the withholding of shares to cover tax obligations and beneficial ownership through a trust.

Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals, disposed of 6,419 ordinary shares to cover tax withholding obligations related to vesting restricted share units.

Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, sold 16,619 ordinary shares at an average price of $15.6883 per share under a pre-arranged trading plan.

Centessa Pharmaceuticals CEO Saurabh Saha sold 55,000 ordinary shares at an average price of $16.527 per share under a pre-arranged Rule 10b5-1 trading plan.

Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, sold 30,000 ordinary shares at $17 per share on September 10, 2024, according to a pre-arranged trading plan.

Centessa Pharmaceuticals CEO Saurabh Saha sold 175,000 ordinary shares at an average price of $16.5247, while also exercising options to acquire 175,000 shares at $5.84.

Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, sold 25,000 ordinary shares at $15 per share on September 9, 2024, as part of a pre-arranged trading plan.

Centessa Pharmaceuticals' CEO, Saurabh Saha, sold 46,651 ordinary shares at a weighted average price of $12.3021, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, sold a portion of his holdings in ordinary shares under a pre-arranged Rule 10b5-1 trading plan.

Centessa Pharmaceuticals CEO Saurabh Saha sold ordinary shares between August 20 and August 22, 2024, under a pre-arranged Rule 10b5-1 trading plan.

David M. Chao, Chief Administrative Officer of Centessa Pharmaceuticals plc, disposed of 10,385 ordinary shares to cover tax withholding obligations related to the vesting of restricted share units.

Iqbal Hussain, General Counsel of Centessa Pharmaceuticals, reports the disposal of 7,520 ordinary shares to cover tax obligations and discloses beneficial ownership of 205,010 ordinary shares directly and 5,500 indirectly through a spouse.

Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, reports the disposal of shares to cover tax withholding obligations related to vesting restricted share units.

CEO Saurabh Saha reports the withholding of 36,263 ordinary shares by Centessa Pharmaceuticals to cover tax obligations related to vesting restricted share units, alongside holdings of 831,924 directly owned shares and 38,000 shares held in trust.

Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals, disposed of 6,419 ordinary shares to cover tax withholding obligations related to vesting restricted share units.

John J. Crowley, Chief Financial Officer of Centessa Pharmaceuticals, was granted stock options for 600,000 ordinary shares on July 1, 2024.